Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

M, Kropff; G, Bisping; E, Schuck; P, Liebisch; N, Lang; M, Hentrich; T, Dechow; N, Kröger; H, Salwender; B, Metzner; O, Sezer; M, Engelhardt; HH, Wolf; H, Einsele; S, Volpert; A, Heinecke; WE, Berdel; J, Kienast

doi:10.1111/j.1365-2141.2007.06656.x

Public

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Shared by NobleBlocks on Aug 1, 2007 • 12:00 AM UTC

Authors:

Kropff M

Bisping G

Schuck E

Abstract

A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week tre...

Discussions